Patisiran - CISMeF

Preferred Label : Patisiran;

NCIt synonyms : RNAi Therapeutic-targeting Transthyretin ALN-TTR02;

NCIt definition : A lipid nanoparticle (LNP)-based formulation consisting of small-interfering RNAs (siRNAs) directed against transthyretin (TTR) encapsulated in lipids, which has potential use in the treatment of TTR-mediated amyloidosis (ATTR). Upon intravenous administration of patisiran, the lipid formulation promotes the uptake by cells. The siRNAs bind to TTR mRNAs, which may result in the inhibition of both the translation and expression of the TTR protein. ATTR is caused by mutations in the TTR gene and results in the formation of abnormal amyloid proteins that accumulate in and cause damage to various body organs and tissues.;

UNII : 50FKX8CB2Y;

CAS number : 1420706-45-1;

Drug name : Patisiran;

Molecule name : ALN-TTR02; ALN-18328;

Détails

Origin ID

C116792;

UMLS CUI

C3896714;

Currated CISMeF NLP mapping
- Patisiran [ICD-11 Extension code]
- Patisiran [SMS substance]
- Patisiran (substance) [SNOMED CT concept]
- patisiran [MeSH Supplementary Concept]
- patisiran [MeSH concept]
See also inter- (CISMeF)
- Product containing patisiran (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Patisiran (substance) [SNOMED CT concept]
- Product containing patisiran (medicinal product) [SNOMED CT concept]
- patisiran [ATC Code]
- patisiran [MeSH Supplementary Concept]
Validated automatic mappings to BTNT
- patisiran [ATC Code]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients